The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), in collaboration with Geneva and Gilead Sciences, Inc., has announced that the U.S. Food and Drug Administration (FDA) has provided formal regulatory agreement for use of an animal model to support development of a drug candidate, remdesivir, for treating deadly Ebola virus (EBOV) infections. USAMRIID
Category: Research Highlights
Geneva President Elise Huszar presented the 2017 Researcher of the Year (ROY) award to Dr. Vincent Ho, Chair of Radiology at Uniformed Services University (USU), earlier today at the USU Faculty Assembly. This award honors an individual who, in partnership with Geneva, spearheads innovative medical research within the U.S. military for the benefit of service members and
Congratulations to Geneva Principal Investigator Dr. Gustavo Palacios of USAMARIID, who recently had his study on bat immunity to the lethal Marburg filovirus published in the prestigious journal CELL. Over the course of its three-decade history, CELL has been a particularly selective journal, only publishing research of significance that helps form the core of life science research.
Geneva researcher, Dr. Gustavo Palacios lectured on the “Effect of Real Time Genomic Surveillance on Health Policy: Lessons Learned from the Liberian Ebola Outbreak” at the Readiness Acceleration & Innovation (RAIN) Network SuperHero of Science Lecture Series held on 8 January 2018. Dr. Palacios is the Director of the Center for Genomic Sciences and the